Breaking the Barriers to Access a Low Cost Intra-Dermal Rabies Vaccine Through Innovative “Pooling Strategy”

Omesh K Bharti, Wim Van Damme, Kristof Decoster, Petros Isaakidis, An Appelmans, Vidya Ramachandran, Archana Phull

Government of Himachal Pradesh, Shimla, India.
Institute of Tropical Medicine, Antwerp, Belgium.
National Institute of Epidemiology, Chennai, India.
Working Journalist in Shimla, Shimla, India.

DOI: 10.4236/wjv.2012.23016                

Abstract

Background: In India every year an estimated 20,000 patients die of Rabies. Major reason for poor compliance to anti-rabies prophylaxis is the high cost of anti-rabies vaccine being prescribed intramuscularly (IM) as a routine i.e. 44.5 USD per course of five injections. In 1992 WHO recommended low cost intra-dermal rabies vaccination (IDRV), which costs only 7.5 USD or less per animal bite course. Methods: Interviews with doctors revealed that they were not prescribing intra-dermal anti rabies vaccination as they were either not aware or were not confident of this route of rabies vaccination. Also the vaccine vial did not have the label for “intra-dermal use”. These barriers were removed by advocacy efforts with policy makers & drug companies, credit sharing & team building, which led to starting of first intra dermal anti-rabies clinic of North India on 2^nd August 2008. Results: Within a month of start of intra-dermal rabies vaccination clinic, i.e. by 2^nd September, 2008, there was an increase in the hospital patient load by 2.8 times, and poor patients load by 3.2 times. In just less than two-year time, 200,000 USD of poor patients were saved and 5769 patients vaccinated. Each patient was asked to bring one vial on first visit & rest of doses were given “free” by pooling strategy. Pooling strategy involved distribution of one vial of vaccine among four persons and keep the three vials for use one by one by all the four patients on subsequent three visits. Another offshoot of the strategy was to prevent wasting of even few drops of vaccine that used to remain in each vial of 1 ml after distribution among four patients (0.2 mL or less). Out of more than 5000 vials utilised, every time we would transfer the left out drops of vaccine to the next new vial and use it immediately on a new pool of patients waiting for vaccination. We would, however, discard the unused vaccine after eight hours of reconstitution at the end of the day. The vaccine so saved turned to be a stock of more than 100 vials in less than two years that we were able to give free to more than 225 rag pickers, garbage collectors and newspaper hawkers on World Rabies Day, Sep 28, 2010. Conclusions: With intra-dermal clinic, we were able to successfully introduce the new cost effective intra-dermal method of rabies vaccination despite all odds & vested interests of companies & old mindset of doctors that had blocked this technique till now. This will go a long way in reducing the burden of disease & death due to rabies from India.

Keywords

Intra-Dermal Route For Anti-Rabies Vaccination; Rabies

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. L. Knobel, S. Cleveland, P. G. Coleman, E. M. Fèvre, M. I. Meltzer, et al., “Re-Evaluating the Burden of Rabies in Africa and Asia,” Bulletin of the World Health Organization, Vol. 83, No. 5, 2005, pp. 360-368.
[2]	M. K. Sudershan, “Assessing Burden of Rabies in India WHO Sponsored National Multi-Centric Survey 2003,” Association for Prevention and Control of Rabies in India, AMS Code 1079420, 2004.
[3]	T. Burki, “The Global Fight against Rabies,” The Lancet, Vol. 372, No. 9644, 2008, pp. 1135-1136. doi:10.1016/S0140-6736(08)61462-2
[4]	World Health Organization, “WHO Expert Consultation on Rabies: First Report,” World Health Organization, Geneva, 2005 (WHO Technical Report Series, No. 931).
[5]	S. D. Semple, “Scientific Memoirs by Officers of the Medical and Sanitary Departments of the Government of India,” No. 44, New Series, Calcutta, 1911.
[6]	S. Madhusudana, “Rabies,” Mc Millan Medical Communications, Gurgaon, 2011, p. 151.
[7]	Average Prices in India 2010 as reference.
[8]	World Health Organization, “WHO Expert Committee on Rabies, 8th Report,” World Health Organization, Geneva, 1992.
[9]	S. Madhusudana, “Rabies,” Mc Millan Medical Communications, Gurgaon, 2011, p. 150.
[10]	Departmental Communication from Chief Medical Officer, Unpublished Document, Hamirpur, 2009.
[11]	“Multicentric Study on the Use of Intradermal Administration of Tissue Culture Antirabies Vaccines in India,” Web Document, pp. 12-15. http://icmr.nic.in/annual/2004-05/nie/clinical_trials.pdf
[12]	Rabipur, Virorab and Indirab Brands in India Allow Intra-Dermal Use Apart from Intramuscular Use and Write “For IM/ID Use”.
[13]	M. J. Warrell, A. Riddell, L.-M. Yu, J. Phipps, L. Diggle, et al., “A Simplified 4-Site Economical Intradermal Post-Exposure Rabies Vaccine Regimen: A Randomised Controlled Comparison with Standard Methods,” PLoS Neglected Tropical Diseases, Vol. 2, No. 4, 2008, p. e224. doi:210.1371/journal.pntd.0000224
[14]	CDC, “Mass Treatment of Humans Who Drank Unpasteurized Milk from Rabid Cows—Massachusetts, 1996-1998,” MMWR Weekly, Vol. 48, No. 11, 1999, pp. 228-229.
[15]	PATH, “Intradermal Delivery of Vaccines: A Review of the Literature and Potential for Development for Use in Low- and Middle-Income Countries,” Program for Appropriate Technology in Health (PATH), Seattle, 2009.
[16]	J. K. Hickling, K. R. Jones, M. Friede, D. Zehrung, D. Chen and D. Kristensen, “Intradermal Delivery of Vaccines: Potential Benefits and Current Challenges,” Bulletin of the World Health Organization, Vol. 89, 2011, pp. 221-226. doi:10.2471/BLT.10.079426